Rates of all-cause death or disabling stroke are similar long-term in patients with aortic stenosis (AS) who undergo transcatheter aortic valve replacement (TAVR) versus surgery, and patients who receive TAVR have higher rates of reintervention, 6-year results from the Evolut Low Risk trial show.